Our operating basic principle is to offer reliable and efficient top quality products, therefore every SIA Interlux product is thoroughly tested and traced in different stages of its life cycle. Our Pharmacovigilance Group ensures the monitoring of safety use of medicinal products for which we are marketing authorization holders on the market. Also the Pharmacovigilance Group shall carry out the following:
Identify new potential risks that may affect the quality, safety and efficacy of the medicinal product,
Evaluates the medicinal products benefit risk ratio,
Provide up-to-date information on the use of medicines to doctors, pharmacists, patients and partners.
SIA Interlux receives safety information from physicians, pharmacists, other healthcare professionals, partners and patients. We will carefully evaluate it and, if necessary, provide the information to the EU safety data base Eudravigilance under supervision of European Medicines Agency. In case of necessity the information might be provided to other pharmacovigilance related Regulatory Authorities and our partners.
Patients, their relatives, doctors, pharmacists, other health care professionals, any other interested persons, if necessary, can and are welcomed to report on SIA Interlux drug side effects to our headquarters via e-mail firstname.lastname@example.org or by phones: working hours: (+371) 67795240 or 24/7 mobile phone (+371) 29115221. In case the information will be submitted to the headquarters, you will receive the information regarding recording and storing of your personal data.
Natālija Utkina; Mg.sc.med.
Deputy of EU Qualified Person Responsible for Pharmacovigilance at SIA Interlux.